March 15, 2018 / 1:18 PM / 2 years ago

BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia

March 15 (Reuters) - Adamas Pharmaceuticals Inc:

* ADAMAS PHARMACEUTICALS INC -

* ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

* ADAMAS PHARMACEUTICALS - ANNOUNCES RESULTS FROM TWO POOLED PHASE 3 STUDIES IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

* ADAMAS PHARMACEUTICALS - THE 2 POOLED PHASE 3 STUDIES SHOWED GOCOVRI-TREATED PATIENTS EXPERIENCED 41 PERCENT FALL IN DYSKINESIA FROM BASELINE AT WEEK 12 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below